Myocardial Steatosis Among Antiretroviral Therapy–Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial
| Autor: | Markella V. Zanni, Karen T. Tashima, Rodney Dawson, Kara W. Chew, Alysse G. Wurcel, Mabel Toribio, Udo Hoffmann, Kathleen V. Fitch, Ntobeko A B Ntusi, Michael D. Nelson, Zsofia D. Drobni, Heather J. Ribaudo, Pamela S. Douglas, Marije van Schalkwyk, Paul E. Sax, Judith S. Currier, Robert K. Bolan, Mamta K. Jain, Alberta L. Warner, Matthew Bidwell Goetz, Gerald S. Bloomfield, Gregory K. Robbins, Lidia S. Szczepaniak, Tricia H. Burdo, Leavitt Morrison, Patrice Desvigne-Nickens, Eric S. Daar, Magid Awadalla, Kim-Lien Nguyen, Vlad G. Zaha, Tomas G. Neilan, Daniel J. Skiest, Steven K. Grinspoon, Raphael J. Landovitz |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Magnetic Resonance Spectroscopy Myocardial steatosis Human immunodeficiency virus (HIV) heart failure Supplement Articles HIV Infections 030204 cardiovascular system & hematology Cardiovascular medicine.disease_cause Medical and Health Sciences Gastroenterology Body Mass Index 0302 clinical medicine cardiometabolic risk intramyocardial triglyceride content Immunology and Allergy 030212 general & internal medicine Intravenous drug Middle Aged Biological Sciences Magnetic Resonance Imaging Heart Disease Infectious Diseases Adipose Tissue Anti-Retroviral Agents 6.1 Pharmaceuticals Female Cardiomyopathies MRS medicine.medical_specialty Clinical Trials and Supportive Activities Diastole Microbiology 03 medical and health sciences Clinical Research Internal medicine medicine Humans cardiovascular magnetic resonance spectroscopy Triglycerides Potential risk business.industry Prevention myocardial steatosis Evaluation of treatments and therapeutic interventions HIV medicine.disease Antiretroviral therapy CD4 Lymphocyte Count Good Health and Well Being Heart Disease Risk Factors Heart failure business Body mass index |
| Zdroj: | The Journal of infectious diseases, vol 222, iss Suppl 1 J Infect Dis |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/jiaa245 |
| Popis: | Background People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart failure precursor. We aimed to characterize myocardial steatosis and associated potential risk factors among a subset of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants. Methods Eighty-two PWH without known heart failure successfully underwent cardiovascular magnetic resonance spectroscopy, yielding data on intramyocardial triglyceride (IMTG) content (a continuous marker for myocardial steatosis extent). Logistic regression models were applied to investigate associations between select clinical characteristics and odds of increased or markedly increased IMTG content. Results Median (Q1, Q3) IMTG content was 0.59% (0.28%, 1.15%). IMTG content was increased (> 0.5%) among 52% and markedly increased (> 1.5%) among 22% of participants. Parameters associated with increased IMTG content included age (P = .013), body mass index (BMI) ≥ 25 kg/m2 (P = .055), history of intravenous drug use (IVDU) (P = .033), and nadir CD4 count Conclusions A substantial proportion of antiretroviral therapy–treated PWH exhibited myocardial steatosis. Age, BMI ≥ 25 kg/m2, low nadir CD4 count, and history of IVDU emerged as possible risk factors for myocardial steatosis in this group. Clinical Trials Registration NCT02344290; NCT03238755. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|